Does UPADACITINIB Cause Interstitial lung disease? 187 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 187 reports of Interstitial lung disease have been filed in association with UPADACITINIB (Rinvoq). This represents 0.3% of all adverse event reports for UPADACITINIB.
187
Reports of Interstitial lung disease with UPADACITINIB
0.3%
of all UPADACITINIB reports
30
Deaths
91
Hospitalizations
How Dangerous Is Interstitial lung disease From UPADACITINIB?
Of the 187 reports, 30 (16.0%) resulted in death, 91 (48.7%) required hospitalization, and 8 (4.3%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 187 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which UPADACITINIB Alternatives Have Lower Interstitial lung disease Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL